Protagonist Therapeutics Return on Tangible Equity 2015-2022 | PTGX

Current and historical return on tangible equity values for Protagonist Therapeutics (PTGX) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Protagonist Therapeutics Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2022-03-31 $-0.12B $0.30B -38.17%
2021-12-31 $-0.13B $0.30B -40.45%
2021-09-30 $-0.11B $0.33B -35.24%
2021-06-30 $-0.08B $0.36B -30.77%
2021-03-31 $-0.07B $0.26B -31.96%
2020-12-31 $-0.07B $0.28B -38.82%
2020-09-30 $-0.07B $0.17B -54.17%
2020-06-30 $-0.07B $0.17B -72.10%
2020-03-31 $-0.08B $0.06B -103.11%
2019-12-31 $-0.08B $0.08B -85.56%
2019-09-30 $-0.07B $0.10B -74.30%
2019-06-30 $-0.07B $0.08B -62.56%
2019-03-31 $-0.05B $0.10B -41.26%
2018-12-31 $-0.04B $0.11B -34.78%
2018-09-30 $-0.03B $0.12B -24.79%
2018-06-30 $-0.03B $0.11B -24.88%
2018-03-31 $-0.03B $0.12B -34.93%
2017-12-31 $-0.04B $0.12B -46.98%
2017-09-30 $-0.05B $0.06B -63.83%
2017-06-30 $-0.05B $0.06B -58.57%
2017-03-31 $-0.04B $0.08B -72.90%
2016-12-31 $-0.04B $0.09B -106.47%
2016-06-30 $-0.02B $-0.05B 191.30%
2016-03-31 $-0.02B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.385B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00